Prothena Corp. Company Profile (NASDAQ:PRTA)

Analyst Ratings

Consensus Ratings for Prothena Corp. (NASDAQ:PRTA) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $74.60 (40.30% upside)

Analysts' Ratings History for Prothena Corp. (NASDAQ:PRTA)
Show:
DateFirmActionRatingPrice TargetActions
7/18/2016Royal Bank Of CanadaReiterated RatingOutperform$95.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/5/2016WedbushReiterated RatingOutperform$77.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2016Barclays PLCInitiated CoverageOverweight$60.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$77.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/19/2015Ladenburg ThalmannBoost Price TargetBuy$49.00 -> $57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/5/2014Bank of America Corp.DowngradeNeutral -> UnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/4/2014Citigroup Inc.Lower Price TargetBuy$60.00 -> $37.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/23/2014 forward)

Earnings

Earnings History for Prothena Corp. (NASDAQ:PRTA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/3/2016Q116($0.77)($0.81)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2016Q215($0.81)($0.76)$0.39 million$0.31 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2015($0.66)($0.73)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q2($0.56)($0.59)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015($0.59)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/5/2015Q414($0.66)($0.48)$1.20 million$2.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2014Q314($0.60)($0.48)$1.13 million$1.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2014Q214$0.06$15.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014$0.81$0.78ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014Q113($0.52)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/28/2013Q412($0.82)$0.13 million$0.58 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Prothena Corp. (NASDAQ:PRTA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.82)($0.82)($0.82)
Q2 20162($0.90)($0.90)($0.90)
Q3 20162($1.01)($0.99)($1.00)
Q4 20162($1.14)($1.13)($1.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Prothena Corp. (NASDAQ:PRTA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Prothena Corp. (NASDAQ:PRTA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/20/2016Arthur W HomanInsiderSell9,375$52.14$488,812.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2016Karin L WalkerInsiderSell4,000$45.11$180,440.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/4/2016Dennis J SelkoeDirectorSell5,000$45.00$225,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2016Karin L. WalkerinsiderSell4,000$50.96$203,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Tara NickersoninsiderSell10,000$66.17$661,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2015Tran NguyenCFOSell30,000$66.17$1,985,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Dennis J. SelkoeDirectorSell3,125$68.74$214,812.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/27/2015Christopher S. HenneyDirectorSell5,000$75.00$375,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2015Lars EkmanDirectorSell30,000$73.35$2,200,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2015Martin KollerinsiderSell30,000$65.03$1,950,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Arthur W. HomaninsiderSell3,125$52.14$162,937.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2015Christopher S. HenneyDirectorSell5,000$55.00$275,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2015Tara NickersoninsiderSell10,000$56.06$560,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2015Martin KollerinsiderSell30,000$55.56$1,666,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Dennis J. SelkoeDirectorSell3,125$55.45$173,281.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Dale B. SchenkCEOSell30,000$56.65$1,699,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015Karin L WalkerInsiderSell7,000$62.06$434,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015Tara NickersonInsiderSell12,000$44.41$532,920.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/20/2015Tara NickersonInsiderSell13,000$39.99$519,870.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/9/2015Dennis J SelkoeDirectorSell3,125$25.56$79,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2014Karin L WalkerInsiderSell2,500$20.74$51,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2014Arthur W HomanInsiderBuy2,000$19.12$38,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2014Karin L WalkerInsiderSell8,000$21.58$172,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Dale SchenkCEOBuy8,000$20.79$166,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2014Tara NickersonInsiderBuy1,656$21.00$34,776.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Gene KinneyInsiderBuy2,500$19.54$48,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2014Tran NguyenCFOBuy2,200$19.61$43,142.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/3/2014Co Plc Perrigomajor shareholderSell3,182,253$24.96$79,429,034.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Prothena Corp. (NASDAQ:PRTA)
DateHeadline
07/23/16 09:49 AMProthena Corporation Plc Ord WI (NASDAQ:PRTA) Shorts Decreased by 6.09% After Short Covering - Consumer Eagle
07/22/16 05:47 PMInsiders Are Selling – Prothena Corporation plc (NASDAQ:PRTA)
07/22/16 05:47 PMChief Legal Officer of Prothena Corporation plc (NASDAQ:PRTA), Homan Arthur W, sells 9,375 shares worth $488,813
07/19/16 06:05 PMShares of Prothena Corporation plc (PRTA) Rally 10.79% - Trade Calls
07/19/16 04:49 AMHot Alert: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), Prothena Corporation plc (NASDAQ:PRTA), Tandem Diabetes ... - KC Register
07/18/16 03:12 PMProthena Corp. Plc – Value Analysis (NASDAQ:PRTA) : July 18, 2016 -
07/16/16 09:13 AMProthena Corporation plc (PRTA) Drops 8.79% on July 13 - Equities.com
07/14/16 06:12 PMProthena Corporation plc (NASDAQ:PRTA) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 06:12 PMProthena Corporation plc Realized Volatility Hits Extreme Level - CML News
07/14/16 09:34 AMCould Prothena Corporation PLC Recover After Today's Huge Decline? - Consumer Eagle
07/14/16 09:34 AMAnalyst Target and Average Rating Watch: Prothena Corporation plc (NASDAQ:PRTA) - Press Telegraph
07/14/16 09:34 AMProthena Corporation plc (PRTA) Jumps 7.39% on July 12 - Equities.com
07/12/16 06:10 PMProthena Corporation plc (PRTA) Jumps 7.39% on July 12
07/12/16 04:31 PMPROTHENA CORP PLC Files SEC form 8-K, Termination of a Material Definitive Agreement -
07/12/16 10:20 AMProthena Corporation Plc Ord WI (NASDAQ:PRTA) Short Interest Increased By 3.99% - Press Telegraph
07/12/16 10:20 AMWere Analysts Bullish Prothena Corporation PLC (NASDAQ:PRTA) This Week? - Press Telegraph
07/11/16 08:05 AMProthena Corp. Plc breached its 50 day moving average in a Bullish Manner : PRTA-US : July 11, 2016 -
07/10/16 05:14 PMIs $95 Within Reach For Prothena Corporation plc (NASDAQ:PRTA)? - Investor Newswire
07/08/16 05:57 PMProthena to Participate in Cantor Fitzgerald’s 2nd Annual Healthcare Conference
07/08/16 03:24 PMPROTHENA CORP PLC Files SEC form 8-K/A, Submission of Matters to a Vote of Security Holders -
07/08/16 08:50 AMProthena Corporation Plc Ord WI (NASDAQ:PRTA) Sellers Increased By 3.99% Their Shorts - Press Telegraph
07/08/16 08:50 AMProthena Corporation PLC (PRTA)'s Amyloidosis Pipeline In Focus - Insider Monkey (blog)
07/08/16 08:50 AMBroker Outlook For Prothena Corporation Plc (NASDAQ:PRTA) - Fiscal Standard
07/07/16 05:59 PMCompany Stock Focus for Prothena Corporation plc (NASDAQ:PRTA): Which Way Will Shares Head? - Press Telegraph
07/07/16 05:59 PMProthena Corporation PLC (NASDAQ:PRTA)'s Amyloidosis Pipeline In Focus - Market Exclusive
07/06/16 06:11 PMProthena Corporation plc: Prothena to Participate in Cantor Fitzgerald's 2nd Annual Healthcare Conference
07/06/16 03:11 PMProthena to Participate in Cantor Fitzgerald's 2nd Annual Healthcare Conference - [at noodls] - DUBLIN, Ireland, July 06, 2016 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel ...
07/06/16 01:24 PMProthena Corporation PLC (PRTA)’s Amyloidosis Pipeline In Focus -
07/06/16 10:35 AMForm 8-K Prothena Corp plc For: Jul 05
07/06/16 10:35 AMProthena Corporation PLC (NASDAQ:PRTA)’s Amyloidosis Pipeline In Focus
07/05/16 10:25 AMToday's Stocks: Prothena Corporation plc (NASDAQ:PRTA), Harley-Davidson, Inc. (NYSE:HOG), Cobalt International ... - KC Register
07/05/16 10:25 AMProthena Corp. (PRTA) Announces New Data from NEOD001 Phase 1/2; Organ Systems Improvements Notes - StreetInsider.com
07/05/16 06:34 AMPROTHENA CORP PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
07/05/16 06:11 AMProthena Presents New Data from Phase 1/2 Study of NEOD001 Demonstrating Improvements in Three Organ Systems in Previously-Treated Patients with AL Amyloidosis - [at noodls] - New data from Phase 1/2 dose-escalation (n=27) and expansion (n=42) study show best response rates in total cardiac- and renal- evaluable patients of 53% and 63%, respectively, that are consistent with ...
07/02/16 05:34 PMProthena Corporation plc (NASDAQ:PRTA) Expected to Reach Highs Of $95 - Investor Newswire
07/01/16 08:42 AMProthena Corporation plc (PRTA) Jumps 7.04% on June 28 - Equities.com
06/28/16 10:47 AMProthena Corporation Plc Ord WI (NASDAQ:PRTA) Sellers Increased By 3.99% Their Shorts - Engelwood Daily
06/25/16 09:40 AMProthena Corporation plc (PRTA) Jumps 6.24% on June 23 - Equities.com
06/22/16 05:53 PMProthena Corporation plc (NASDAQ:PRTA) Stock Momentum Hits Weakness - CML News
06/22/16 05:53 PMNew Broker Ratings For Prothena Corporation Plc (NASDAQ:PRTA) - FTSE News
06/21/16 03:19 PMProthena to Present at 15th International Symposium on Amyloidosis Showcasing Broad Commitment to Advancing New Therapies for Systemic Amyloidoses - [at noodls] - New clinical data to be presented from Phase 1/2 dose-escalation and expansion trial of NEOD001 for the potential treatment of AL amyloidosis Presentations to highlight data from clinical, preclinical ...
06/20/16 07:31 AMThis Weeks Broker Views For Prothena Corporation Plc (NASDAQ:PRTA) - Fiscal Standard
06/18/16 10:05 AMWeak On High Volume: Prothena (PRTA) - TheStreet.com
06/17/16 07:21 AMProthena Corp. Plc breached its 50 day moving average in a Bearish Manner : PRTA-US : June 17, 2016 -
06/16/16 10:08 AMHot News: Prothena Corporation plc (NASDAQ:PRTA), Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), KMG ... - KC Register
06/10/16 06:12 PMProthena (PRTA) Flagged As Strong On High Volume - TheStreet.com
06/10/16 08:57 AMProthena Corporation PLC: Credit Suisse Says PRX003 Potential Sales Add to Valuation - Bidness ETC
06/09/16 06:22 PMProthena Corp. (PRTA) Says PRX003 Phase 1 as Novel Anti-MCAM Antibody Met Primary Objective - StreetInsider.com
06/09/16 03:09 PMProthena Reports Results of Phase 1 Single Ascending Dose Study of PRX003, Demonstrating Target Engagement of the Novel Anti-MCAM Antibody for Inflammatory Diseases - [at noodls] - All doses of PRX003 found to be safe and well tolerated, meeting the primary objective of the Phase 1 single ascending dose study in healthy volunteers Neutralization of Th17 cells of greater than 95 percent ...
06/08/16 06:22 PMPROTHENA CORPORATION PLC (NASDAQ:PRTA) Financial Condition Compared to S&P 500 - CML News

Social

About Prothena Corp.

Prothena Corp. logoProthena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003). The Company has generated monoclonal antibodies that selectively bind to amyloidogenic (diseased) forms of the Transthyretin (TTR)-mediated amyloidosis (ATTR) protein. Its pipeline also includes late discovery-stage programs for which the Company is testing the efficacy of antibodies in preclinical models of diseases related to amyloid or cell adhesion. NEOD001 is a monoclonal antibody that specifically targets the amyloid that accumulates in AL amyloidosis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: PRTA
  • CUSIP:
Key Metrics:
  • Previous Close: $53.35
  • 50 Day Moving Average: $43.96
  • 200 Day Moving Average: $41.76
  • P/E Ratio: N/A
  • P/E Growth: 0.11
  • Market Cap: $1.83B
  • Beta: 2.11
  • Current Year EPS Consensus Estimate: $-3.78 EPS
  • Next Year EPS Consensus Estimate: $-3.52 EPS
Additional Links:
Prothena Corp. (NASDAQ:PRTA) Chart for Saturday, July, 23, 2016